FIELD: chemistry.
SUBSTANCE: invention relates to (3aR,6aR)-N-(4-(3-ethylphenylamino)-7-methoxyquinazolin-6-yl)-1-methylhexahydropyrrolo[3,4-b]pyrrole-5(1H)-carboxamide or its pharmaceutically acceptable salt, as well as to a pharmaceutical composition for treatment of the cancer disease, sensible to inhibition of hyper-expression and/or hyperactivity of a receptor of an epidermal growth factor, which contains the claimed compound, a method of the cancer disease treatment, a method of inhibition and to the application of the claimed compound for a drug preparation.
EFFECT: (3aR,6aR)-N-(4-(3-ethylphenylamino)-7-methoxyquinazoline-6-yl)-1-methylhexahydropyrrolo[3,4-b]pyrrole-5(1H)-carboxamide, which shows an inhibition activity to hyperexpression and/or hyperactivity of the epidermal growth factor receptor.
12 cl, 4 tbl, 7 ex
| Title | Year | Author | Number |
|---|---|---|---|
| OCTAHYDROPYRROLO[3,4-b]PYRROLE DERIVATIVES (VERSIONS), METHOD OF OBTAINING OCTAHYDROPYRROLO[3,4-b]PYRROLE DERIVATIVES (VERSIONS), BASED ON THEM PHARMACEUTICAL COMPOSITION AND METHOD OF TREATING DISEASE OR IMPAIRMENT OF STATE OF ORGANISM, SENSITIVE TO MODULATION OF HISTAMINE-3 RECEPTOR ACTIVITY | 2007 |
|
RU2492172C2 |
| OCTAHYDRO-PYRROLO[3,4-b]PYRROL N-OXIDES | 2008 |
|
RU2486187C2 |
| DERIVATIVES OF PYRROLOPYRIMIDINE USEFUL AS JAK-KINASES INHIBITORS | 2012 |
|
RU2618673C2 |
| HETEROCYCLIC COMPOUNDS FOR TYROSINE KINASE 2 ACTIVITY MEDIATION | 2020 |
|
RU2826012C2 |
| SUBSTITUTED PURINE AND 7-DEAZAPURINE COMPOUNDS | 2011 |
|
RU2606514C2 |
| SUBSTITUTED 4-(SELENOPHEN-2(OR 3)-YLAMINO) PYRIMIDINE COMPOUNDS AND METHODS OF USE THEREOF | 2011 |
|
RU2597609C2 |
| QUINAZOLINE INHIBITORS OF ACTIVATING MUTANT FORMS OF EPIDERMAL GROWTH FACTOR RECEPTOR | 2014 |
|
RU2656597C2 |
| COMPOUNDS OF 1-CYANO-PYRROLIDINES AS USP30 INHIBITORS | 2016 |
|
RU2717238C2 |
| SALTS OF A QUINAZOLINE DERIVATIVE AND A METHOD FOR PRODUCTION THEREOF | 2016 |
|
RU2720810C2 |
| PHARMACEUTICAL COMBINATION CONTAINING TNO155 AND RIBOCICLIB | 2020 |
|
RU2813111C2 |
